Differentiation of COVID-19 pneumonitis and ICI induced pneumonitis

DW Dumoulin, HA Gietema, MS Paats… - Frontiers in …, 2020 - frontiersin.org
Immune checkpoint inhibitors (ICI) have become the standard of care treatment for several
tumor types. ICI-induced pneumonitis is a serious complication seen with treatment with …

COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

M Russano, F Citarella, A Napolitano… - Expert opinion on …, 2020 - Taylor & Francis
Introduction The COVID-19 pandemic occurred amid the cancer immunotherapy revolution.
Immune checkpoint inhibitors (ICIs) have become the standard of care for several solid …

[HTML][HTML] Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment

E Rossi, G Schinzari, G Tortora - Journal for Immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The
diagnosis between COVID-19-induced pneumonia and immunotherapy-induced …

[HTML][HTML] Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management

J Naidoo, JE Reuss, K Suresh… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Abstract Immune-related (IR)-pneumonitis is a rare and potentially fatal toxicity of anti-PD (L)
1 immunotherapy. Expert guidelines for the diagnosis and management of IR-pneumonitis …

Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer

CM Lovly, KL Boyd, PI Gonzalez-Ericsson, CL Lowe… - MedRxiv, 2020 - medrxiv.org
Immune checkpoint inhibitors (ICIs) are used for the treatment of numerous cancers, but
risks associated with ICI-therapy during the COVID-19 pandemic are poorly understood. We …

[HTML][HTML] COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma …

A Dipasquale, P Persico, E Lorenzi… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
By the beginning of the global pandemic, SARS-CoV-2 infection has dramatically impacted
on oncology daily practice. In the current oncological landscape, where immunotherapy has …

Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic

HL Chang, PJ Wei, KL Wu, HL Huang… - Lung …, 2020 - lungcancerjournal.info
As of May 27, 2020, 5,612,601 people have been diagnosed with COVID-19 and 349,060
deaths have been recorded, with a mortality rate of up to 6.22% worldwide. Despite the …

[HTML][HTML] Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations

MB Abid - Journal for Immunotherapy of Cancer, 2021 - ncbi.nlm.nih.gov
The clinically indistinguishable overlap between pneumonitis caused due to immune
checkpoint inhibition (ICI) and pneumonia associated with COVID-19 has posed …

[HTML][HTML] COVID-19 and immune checkpoint inhibitors: initial considerations

RJ Sullivan, DB Johnson, BI Rini… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
COVID-19 infections are characterized by inflammation of the lungs and other organs that
ranges from mild and asymptomatic to fulminant and fatal. Patients who are …

Deep learning algorithm trained with COVID-19 pneumonia also identifies immune checkpoint inhibitor therapy-related pneumonitis

CA Mallio, A Napolitano, G Castiello, FM Giordano… - Cancers, 2021 - mdpi.com
Simple Summary The use of immune checkpoint inhibitors (ICIs) to treat oncologic diseases
is progressively increasing. Computed tomography (CT) features of ICI therapy-related …